Expression profiling of muscle invasive and non-invasive bladder tumors for biomarkers identification related to drug resistance, sensitivity and tumor progression
Open Access
- 1 January 2020
- journal article
- research article
- Published by Taylor & Francis in Biotechnology & Biotechnological Equipment
- Vol. 34 (1) , 506-514
Abstract
Many bladder cancer (BC) patients with early disease are asymptomatic and diagnosed at advanced stage when the therapeutic options are limited. This necessitates the development of reliable predictive molecular biomarkers that will ensure a positive therapeutic response in every patient. The aim of this study was to screen for alterations in gene expression levels related to drug sensitivity and resistance that may be further explored as potential predictive therapeutic biomarkers. Gene expression analysis of the 168 genes from two panels for Cancer drug resistance and metabolism (PAHS004) and Cancer Drug Targets (PAHS507z) was performed. A total of 47 transitorial cell bladder cancer samples of stage pTa, pT1, pT2 were investigated using the pooling method, which allows reducing the effect of biological variation and detecting only significant expression changes. Differential gene expression was calculated using the ΔΔCt method with GPDH as a housekeeping gene. The 4.0-fold change in gene expression was used as the cut-off threshold to determine upregulation or downregulation compared to normal bladder tissue (negative control). Significance of the differences in the expression profiles was assessed by nonparametric one-way analysis of variance (ANOVA) with Dunn’s multiple comparison tests and Mann-Witney test. We demonstrated a correlation of tumor invasion and several up-regulated genes related to chemotherapy resistance. For the first time, this study demonstrated overexpression of CDK8, CDK9, FIGF, HDAC11, IGF1 and PDGFRA genes in muscle-invasive bladder carcinomas. These genes and their proteins could be used as potential biomarkers for bladder cancer progression or prospective therapeutic targets.Keywords
This publication has 40 references indexed in Scilit:
- HDAC11 is a novel drug target in carcinomasInternational Journal of Cancer, 2012
- Pathologic Downstaging Is a Surrogate Marker for Efficacy and Increased Survival Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Urothelial Bladder CancerEuropean Urology, 2012
- Activation of the aryl hydrocarbon receptor pathway enhances cancer cell invasion by upregulating the MMP expression and is associated with poor prognosis in upper urinary tract urothelial cancerCarcinogenesis, 2009
- Apoptosis of metastatic prostate cancer cells by a combination of cyclin-dependent kinase and AKT inhibitorsThe International Journal of Biochemistry & Cell Biology, 2009
- Imaging Correlates of Leukocyte Accumulation and CXCR4/CXCL12 in Multiple SclerosisArchives of Neurology, 2009
- Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern ChinaJournal of Translational Medicine, 2008
- Gene expression in thyroid autonomous adenomas provides insight into their physiopathologyOncogene, 2005
- Differential expression of the Tie-2 receptor and its ligands in human pancreatic tumorsJournal of the American College of Surgeons, 2004
- CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformationThe Journal of Pathology, 2004
- Expression of Vascular Endothelial Growth Factor Gene and Its Receptor (flt-1) Gene in Urinary Bladder Cancer.The Tohoku Journal of Experimental Medicine, 1998